NCT04517552 (CS1P1) is a clinical trial of [11C]-CS1P1 in Alzheimer Disease, sponsored by Tammie L. S. Benzinger, MD, PhD.

Who is sponsoring NCT04517552?

NCT04517552 is sponsored by Tammie L. S. Benzinger, MD, PhD.

What drugs are being tested in NCT04517552?

Interventions in NCT04517552: [11C]-CS1P1.

What condition does NCT04517552 study?

NCT04517552 studies Alzheimer Disease.

Is NCT04517552 still recruiting?

NCT04517552 is currently active, enrolled. Last updated 7 August 2025.

Last reviewed 2025-08-07 · How we verify

NCT04517552: CS1P1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Investigation of Inflammation Using [C-11]-CS1P1

Active, enrolled Last updated 7 August 2025

What this trial tests

trial testing [11C]-CS1P1 in Alzheimer Disease in 60 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

2 November 2020

Primary endpoint
1 July 2026

8 July 2026

Quick facts

Lead sponsor	Tammie L. S. Benzinger, MD, PhD
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	60
Start date	2 November 2020
Primary completion	1 July 2026
Estimated completion	8 July 2026
Sites	1 location across United States

Drugs / interventions tested

[11C]-CS1P1 — full drug profile →

Conditions studied

Alzheimer Disease — all drugs for Alzheimer Disease →

Sponsor

Tammie L. S. Benzinger, MD, PhD — full company profile →

Who can join

18 and older, any sex, with Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There is a compelling need for a noninvasive imaging approach to measure S1P1 in both preclinical models of diseases and humans. PET measures of S1P1 expression is critical for elucidating the pathophysiological roles of S1P1 in neuroinflammation and neurodegeneration. The relevance of S1P1 in clinical disease has become readily apparent with the FDA approval of the S1P1 modulator FTY720 (fingolimod) for treating relapsing-remitting MS (RR-MS). MS is a chronic autoimmune, inflammatory disease caused by lymphocytic infiltration that leads to demyelinating neurodegenerative disease.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Phase 1 Evaluation of <sup>11</sup>C-CS1P1 to Assess Safety and Dosimetry in Human Participants.
Brier MR, Hamdi M, Rajamanikam J, Zhao H, et al · · 2022 · cited 19× · PMID 35332093 · DOI 10.2967/jnumed.121.263189
Sphingolipids in Lung Pathology in the Coronavirus Disease Era: A Review of Sphingolipid Involvement in the Pathogenesis of Lung Damage.
Khan SA, Goliwas KF, Deshane JS. · · 2021 · cited 17× · PMID 34690821 · DOI 10.3389/fphys.2021.760638
Metabolite Study and Structural Authentication for the First-in-Human Use Sphingosine-1-phosphate Receptor 1 Radiotracer.
Qiu L, Jiang H, Cho K, Yu Y, et al · · 2024 · cited 6× · PMID 38634759 · DOI 10.1021/acschemneuro.4c00077
Imaging and targeting S1PR1 in HER2+ tumors.
Shmuel S, Qiu L, Vanover A, Chen H, et al · · 2025 · PMID 40812162 · DOI 10.1016/j.nucmedbio.2025.109057

Verify or expand the search:

Other trials of [11C]-CS1P1

Trials testing the same drug.

NCT06084533 — CS1P1 PET Studies of Neuroinflammation in Parkinson Disease · enrolling by invitation

Other recruiting trials for Alzheimer Disease

Currently open trials in the same condition.

NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting

Other Tammie L. S. Benzinger, MD, PhD trials

Trials by the same sponsor.

NCT04104659 — Study of Tau Imaging With the Use of [18F]MK-6240 Tracer · enrolling by invitation
NCT02707978 — F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD) · Phase 2 · withdrawn
NCT03279523 — F 18 T807 PET (Positron Emission Tomograph )Scan for HIV Infected & Uninfected · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04517552 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tammie L. S. Benzinger, MD, PhD
Last refreshed: 7 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04517552.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing